You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody Drug Conjugates

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

The Rechallenge of ADCs in MBC Patients

Active, not recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 5, 2022

Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy Trial in Shanghai (Disitamab Vedotin and Toripalimab)

Recruiting
  • Muscle Invasive Bladder Cancer
  • +4 more
  • Disitamab Vedotin and Toripalimab
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Jul 31, 2023

Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F

Not yet recruiting
  • Breast Cancer
  • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
  • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
  • (no location specified)
Feb 22, 2023

Metastatic Breast Cancer Trial in Spain (Palbociclib, Trastuzumab, Endocrine therapy)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +34 more
Oct 24, 2022

Pruritus Trial in Baltimore (Obeticholic acid, Linerixibat)

Completed
  • Pruritus
  • Baltimore, Maryland
    GSK Investigational Site
Nov 4, 2022

NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Dec 7, 2022

Advanced or Metastatic Solid Tumors Trial in Toulouse, Villejuif, Barcelona (W0101 - Cohort A1, W0101 - Cohort A2, W0101 -

Active, not recruiting
  • Advanced or Metastatic Solid Tumors
  • W0101 - Cohort A1
  • +2 more
  • Toulouse, France
  • +2 more
Dec 19, 2022

Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Neuroendocrine Carcinomas
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

Drug Antibody and Precision Transfusion in China

Recruiting
  • Drug-specific Antibodies
    • Guangzhou, Gaungdong, China
      Nanfang hospital of southern medical university
    Nov 2, 2022

    Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

    Withdrawn
    • Relapsed Solid Neoplasm
    • +2 more
    • STI-3258
    • (no location specified)
    Jan 24, 2023

    Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Trial in Tempe (CCX168, Midazolam, Celecoxib)

    Completed
    • Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
    • Tempe, Arizona
      Celerion
    Aug 15, 2023

    HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

    Recruiting
    • HR Positive/HER2 Low Expression Metastatic Breast Cancer
    • Disitamab vedotin
    • Endocrine therapy
    • Guangzhou, Guangdong, China
    • +2 more
    Jun 19, 2023

    Light Chain (AL) Amyloidosis Trial (STI-6129)

    Not yet recruiting
    • Light Chain (AL) Amyloidosis
    • STI-6129
    • (no location specified)
    Jan 11, 2023

    Reporting of Antibody-Drug Conjugate Associated Sepsis-related

    Completed
    • Sepsis (SMQ)
    • +2 more
    • Antibody-Drug Conjugate
    • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
    • Changsha, Hunan, China
      Central South University
    Jun 19, 2022

    Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

    Not yet recruiting
    • Multiple Cancer
    • Colorectal Cancer
    • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
    • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
    • (no location specified)
    Aug 20, 2023

    Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection Trial run by the National Institute of Allergy and Infectious Diseases

    Not yet recruiting
    • Multi-Drug Resistant Hiv-1 Infection
    • HIV-1 Infection
    • UB-421
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Charcot Joint of Foot Trial in Chandigarh (Danosumab)

    Active, not recruiting
    • Charcot Joint of Foot
    • Chandigarh, India
      Deptt of Endocrinology
    Mar 21, 2023

    Solid Tumor Trial in Worldwide (BYON3521)

    Recruiting
    • Solid Tumor
    • Brussels, Belgium
    • +3 more
    Aug 2, 2022

    Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • STI-6129
    • Beijing, Beijing, China
    • +3 more
    Jan 9, 2023

    Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

    Recruiting
    • Recurrent Angioimmunoblastic T-Cell Lymphoma
    • +13 more
    • Brentuximab Vedotin
    • Pembrolizumab
    • Chicago, Illinois
      Northwestern University
    Jun 15, 2022

    Cancer Trial (Antibody-Drug Conjugate)

    Not yet recruiting
    • Cancer
    • Antibody-Drug Conjugate
    • (no location specified)
    Aug 23, 2023

    Advanced Solid Tumor Trial in New York (STI-6129)

    Not yet recruiting
    • Advanced Solid Tumor
    • STI-6129
    • New York, New York
      Columbia University Medical Center
    Jan 26, 2023

    Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

    Recruiting
    • Light Chain (AL) Amyloidosis
    • STI-6129
    • Duarte, California
    • +3 more
    Jan 12, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial (BN301)

    Not yet recruiting
    • B-cell Lymphoma
    • +4 more
    • (no location specified)
    Nov 9, 2022